Descrizione del progetto
I LED trattano importanti effetti collaterali della radioterapia
L’aumento dell’invecchiamento della popolazione abbinato alla diagnosi precoce e al trattamento del cancro porterà molte persone a vivere per anni con tale condizione, richiedendo trattamenti potenzialmente ricorrenti. La mucosite orale e la radiodermatite sono gravi effetti collaterali della radioterapia. Fino a poco tempo fa, il trattamento di questi effetti collaterali era per lo più palliativo. Nell’ultimo decennio, è stata utilizzata con un certo successo la fotobiomodulazione con laser. Nuove ricerche tuttavia suggeriscono che la luce laser ad alta intensità non sia richiesta. Il progetto CareMin650, finanziato dall’UE, ha creato un dispositivo di fototerapia basato su diodi a emissione di luce (LED) con lo stesso nome, che è stato convalidato nei pazienti, dimostrandosi sicuro ed efficace. Ora sarà diretto sul mercato.
Obiettivo
Today the healthcare system is under great pressure due to the increasing incidence of cancer, which is also affected by ageing of the population. However, all efforts in the medical industry have concentrated on early diagnosis and treatment of cancer, so that this is becoming a chronic disease. The surfacing challenge from now on will be improving the quality of life of cancer patients.
Mucositis and radiodermatitis are the most common and most debilitating side effects suffered by cancer patients but, so far, there is no approved preventive or curative treatment. In the last years, photobiomodulation has gained traction but the technology is still expensive, complex and inaccurate. CareMin650 is an innovative LED-based phototherapy device that will make photobiomodulation for the treatment of these conditions accurate, easy and inexpensive, thanks to its flexible fabric made of woven optic fibre. Neomedlight is proprietary of this core technology and knows a previous market success across Europe applying it to the niche market of jaundice treatment with Bilicocoon®. We now have validated the reliability of CareMin650 to deliver a fast, comfortable and painless treatment for patients; these are the added values to our central value proposition: a system for preventive and curative delivery of an accurate dose of red light. Moreover, this is a cost-effective solution to increase the quality of life and the survival of cancer patients: In the EU alone, CareMin650 will contribute to reduce the 200,000 cancer deaths and the €27.9 billion economic burden associated to mucositis and radiodermatitis. We have a huge untapped market ahead and now want to finalise CareMin650 development and achieve market preparedness. The SME Phase 2 project will allow NeoMedLight to put on the market a medical device that will boost the growth of the company, with an expected €20.8 million cumulative profit, a ROI of 5.08 and from 8 to 20 new job positions by 2025.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-2
Meccanismo di finanziamento
SME - SME instrumentCoordinatore
69100 VILLEURBANNE
Francia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.